Levetiracetam in tardive dyskinesia: An open label study

Movement Disorders

Volumn 21, Issue 8, 2006, Pages 1219-1221

  Konitsiotis, Spiros ^a   Pappa, Sofia ^a   Mantas, Christos ^a   Mavreas, Venos ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Antipsychotics; Levetiracetam; Tardive dyskinesia

Indexed keywords

AMITRIPTYLINE; BIPERIDEN; CLOZAPINE; DIAZEPAM; ETIRACETAM; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELUSIONAL DISORDER; DRUG EFFICACY; DRUG INDUCED DISEASE; FATIGUE; FEMALE; HUMAN; MALE; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA;

ADULT; AGED; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; HUMANS; MIDDLE AGED; NOOTROPIC AGENTS; PIRACETAM; SINGLE-BLIND METHOD;

EID: 33748346041     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20835     Document Type: Article

References (15)

1. Klitgaard H, Matagne A, Grimee R, Vanneste-Goemaere J, Margineanu DG. Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy. Seizure 2003;12:92-100.
2. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85:77-85.
3. Hill MP, Brotchie JM, Crossman AR, Bezard E, Michel A, Grimee R, Klitgaard H. Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets. Clin Neuropharmacol 2004;27:171-177.
4. Hill MP, Ravenscroft P, Bezard E, et al. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. J Pharmacol Exp Ther 2004;310:386-394.
5. Bezard E, Hill MP, Crossman AR, et al. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. Eur J Pharmacol 2004;485:159-164.
6. Hill MP, Bezard E, McGuire SG, et al. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Mov Disord 2005;20:1205-1209.
7. Zesiewicz TA, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA. Open-label pilot study of levetiracetam (keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Mov Disord 2003;11:1301-1305.
8. McGavin CL, John V, Musser WS. Levetiracetam as a treatment for tardive dyskinesia: a case report. Neurology 2003;51:419.
9. Fehr C, Dahmen N, Klawe C, Eicke M, Szegedi A. Piracetam in the treatment of tardive dyskinesia and akathisia: a case report. J Clin Psychopharmacol 2001;21:248-249.
10. Genton P, Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epilept Disord 2000;2:99-105.
11. Loscher W, Richter A. Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia. Eur J Pharmacol 2000;391:251-254.
12. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-487.
13. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 2000.
14. Meco G, Fabrizio E, Epifanio A, Di Raimondo G, Vanacore N, Morgante L. Levetiracetam in L-dopa-induced dyskinesia. Clin Neuropharmacol 2005;28:102-103.
15. Cerenghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: result of a double blind, randomized clinical trial. Neurology 2000;55:236-242.